Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer

Participants needed: 115
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Celconta Life Science Co., Ltd.Updated: Jul 1, 2025
Eligibility criteria

Voluntarily participate in the clinical trial; fully understand and be informed... [+14]

NSCLC patients who have received neoadjuvant therapy; [+26]

Read more
Status: Recruiting

PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors

A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy after surgery in patients with solid tumors

Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Celconta Life Science Co., Ltd.Updated: Mar 26, 2025Locations: 1
Eligibility criteria

Understand and voluntarily sign the informed consent form; [+16]

Pregnant or lactating women; [+9]

Read more
Status: Recruiting

Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)

A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT225 cell injection in Claudin18.2-positive advanced solid tumors

Participants needed: 18
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenzhen Celconta Life Science Co., Ltd.Updated: Jan 17, 2025Locations: 1
Eligibility criteria

Age 18-75 (including the critical value), regardless of gender; [+16]

Pregnant or breastfeeding women; [+22]

Read more